EICHORCondition: Lung Neoplasm · Sponsor: Merck Sharp & Dohme LLC
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastatic means the cancer has spread to other parts of the body. Standard treatment (usual treatment) for metastatic squamous NSCLC is immunotherapy with or without chemotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. However, standard treatment may not work or may stop working to treat metastatic squamous NSCLC. Researchers want to learn if study treatments that are antibody drug conjugates (ADCs) can treat metastatic squamous NSCLC that did not respond (get smaller or go away) to standard treatment. An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goals of this study are to learn about: * The cancer response to the study treatments compared to chemotherapy * The safety of the study treatments and if people tolerate them This study is one of the substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| University of Kentucky Chandler Medical Center ( Site 0019) | Lexington, Kentucky, United States | Recruiting |
| MedStar Franklin Square Medical Center ( Site 0033) | Baltimore, Maryland, United States | Recruiting |
| Texas Oncology - DFW ( Site 8003) | Dallas, Texas, United States | Recruiting |
| Centro de Estudios Clínicos SAGA ( Site 0161) | Santiago, Region M. de Santiago, Chile | Recruiting |
| FALP ( Site 0160) | Santiago, Region M. de Santiago, Chile | Recruiting |
| Bradfordhill ( Site 0162) | Santiago, Region M. de Santiago, Chile | Recruiting |
| Beijing Cancer Hospital ( Site 0301) | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing University Cancer Hospital ( Site 0304) | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Provincial Cancer Hospital ( Site 0310) | Fuzhou, Fujian, China | Recruiting |
| Guangxi Medical University Cancer Hospital ( Site 0303) | Nanning, Guangxi, China | Recruiting |
| Henan Cancer Hospital ( Site 0311) | Zhengzhou, Henan, China | Recruiting |
| Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 0309) | Nanjing, Jiangsu, China | Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06780098